A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer

Inclusion Criteria

• •Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF).
• •Subject has Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1.
• •Subject has a new clinical or pathologic diagnosis of resectable HPV+ or HPV- SCCHN of the oral cavity, pharynx, or larynx
• •Macroscopic complete resection of the primary tumor must be planned and subjects should have no medical contraindication to surgery.
• •Subject consents to and has tumor accessible for tumor biopsy pre-treatment.
• •Subjects must have acceptable hematopoietic, liver, renal, and coagulation function as assessed by laboratory tests.